JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy
Gu, Yu-Lei; Lan, Chao; Pei, Hui; Yang, Shuang-Ning; Liu, Yan-Fen; Xiao, Li-Li;
  PDF(new window)
 Abstract
Objective: To evaluate the application value of serum CA19-9, CEA, CA125 and CA242 in diagnosis and prognosis of pancreatic cancer cases treated with concurrent chemotherapy. Materials and Methods: 52 patients with pancreatic cancer, 40 with benign pancreatic diseases and 40 healthy people were selected. The electrochemiluminescence immunoassay method was used for detecting levels of CA19-9, CEA and CA125, and a CanAg CA242 enzyme linked immunoassay kit for assessing the level of CA242. The Kaplan-Meier method was used for analyzing the prognostic factors of patients with pancreatic cancer. The Cox proportional hazard model was applied for analyzing the hazard ratio (HR) and 95% confidential interval (CI) for survival time of patients with pancreatic cancer. Results: The levels of serum CA19-9, CEA, CA125 and CA242 in patients with pancreatic cancer were significantly higher than those in patients with benign pancreatic diseases and healthy people (P<0.001). The sensitivity of CA19-9 was the highest among these, followed by CA242, CA125 and CEA. The specificity of CA242 is the highest, followed by CA125, CEA and CA19-9. The sensitivity and specificity of joint detection of serum CA19-9, CEA, CA125and CA242 were 90.4% and 93.8%, obviously higher than single detection of those markers in diagnosis of pancreatic cancer. The median survival time of 52 patients with pancreatic cancer was 10 months (95% CI7.389~12.611).. Patients with the increasing level of serum CA19-9, CEA, CA125, CA242 had shorter survival times (P
 Keywords
Pancreatic cancer;tumor markers;CA19-9;CEA;CA125;CA242;prognosis;
 Language
English
 Cited by
1.
Clinical value of preoperative serum CA 19-9 and CA 125 levels in predicting the resectability of hilar cholangiocarcinoma, SpringerPlus, 2016, 5, 1  crossref(new windwow)
2.
Potential Biomarkers in Lewis Negative Patients With Pancreatic Cancer, Annals of Surgery, 2017, 265, 4, 800  crossref(new windwow)
 References
1.
Bertsch T, Aschenneller C, Bewarder N, et al (2013). European proficiency study with control serum for the tumor marker CA19-9 measured on different test system. Clin Lab, 59, 185-92.

2.
Duraker N, Hot S, Polat Y, et al (2007). CEA, CA19-9, and CA125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice. J Surg Oncol, 95, 142-7. crossref(new window)

3.
Frucht H, Stevens PD, Fogelman DR, et al (2004). Advances in the Genetic Screening, Work-up, and Treatment of Pancreatic Cancer. Curr Treat Options Gastroenterol, 7, 343-54. crossref(new window)

4.
He Y, Zheng R, Li D, et al (2015). Pancreatic cancer incidence and mortality patterns in China, 2011. Chin J Cancer Res, 27, 29-37.

5.
Humphris JL, Chang DK, Johns AL, et al (2012). The prognostic and predictive value of serum CA19-9 in pancreatic cancer. Ann Oncol, 23, 1713-22. crossref(new window)

6.
Jamieson NB, Carter CR, Mckay CJ, et al (2011). Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Clin Cancer Res, 17, 3316-31. crossref(new window)

7.
Jemal A, Siegel R, Ward E, et al (2008). Cancer statistics. CA Cancer J Clin, 58, 71-96. crossref(new window)

8.
Jiang XT, Tao HQ, Zou SC (2004). Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer. Hepatobiliary Pancreat Dis Int, 3, 464-8.

9.
Li XY, Guo XZ, Li HY, et al (2014). Application of tumor markers in diagnosis and prognosis assessment of pancreatic cancinoma. Chin J Prac Int Med, 34, 499-503.

10.
Lin QJ, Yang F, Jin C, et al (2015). Current status and progress of pancreatic cancer in China. World J Gastroenterol, 21, 7988-8003.

11.
Liu F, Du F1, Chen X (2014). Multiple tumor marker protein chip detection system in diagnosis of pancreatic cancer. World J Surg Oncol, 12, 333. crossref(new window)

12.
Mu XF, Cao JX, Wang YX, et al (2011). Clinical value of serum CA19-9, CEA and CA125 in diagnosis and prognosis of unresectable pancreatic cancer patients treated with chemotherapy. Clin Focus, 26, 113-6.

13.
Reitz D, Gerger A, Seidel J, et al (2015). Combination of tumour markers CEA and CA19-9 improves the prognostic prediction in patients with pancreatic cancer. J Clin Pathol, 68, 427-33. crossref(new window)

14.
Wu AZ, Liang Z, Wang HF (2011). Analysis of serum CA19-9, CA242, CA125 and CEA of pancreatic cancer patients. Chin J Lab Diagn, 15, 1087-8.

15.
Zhou G, Niu L, Chiu D, et al (2012). Changes in the expression of serum markers CA242, CA19-9, CEA, TNF x03b1, and TSGF after eryosurgery in pancreatic cancer patients. Biotechnol Lett, 34, 1235-41. crossref(new window)